Payment overview · 2025
General Payments
$171.07
10 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Julius Dibernardo, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1235109851
Verified facts
What the public records show
CMS Open Payments records show Michael Julius Dibernardo, MD received $171.07 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.32 | 18.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.94 | 18.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.59 | 18.5% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $29.03 | 17.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.98 | 10.5% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $14.26 | 8.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.95 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $171.07 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 250 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
250 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
107 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 734 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 547 | 136 |
| Lisinopril | Lisinopril | 481 | 122 |
| Omeprazole | Omeprazole | 359 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 95 |
| Escitalopram Oxalate | Escitalopram Oxalate | 347 | 80 |
| Losartan Potassium | Losartan Potassium | 341 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 74 |
| Celecoxib | Celecoxib | 286 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 271 | 57 |
| Gabapentin | Gabapentin | 267 | 61 |
| Ozempic | Semaglutide | 250 | 39 |
| Tramadol Hcl | Tramadol Hcl | 249 | 50 |
| Simvastatin | Simvastatin | 248 | 59 |
| Meloxicam | Meloxicam | 243 | 57 |
| Metformin Hcl Er | Metformin Hcl | 232 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 46 |
| Prednisone | Prednisone | 216 | 94 |
| Alprazolam | Alprazolam | 207 | 44 |
| Jardiance | Empagliflozin | 197 | 32 |
| Spironolactone | Spironolactone | 197 | 51 |
| Montelukast Sodium | Montelukast Sodium | 183 | 46 |
| Clonazepam | Clonazepam | 178 | 27 |
| Trazodone Hcl | Trazodone Hcl | 159 | 39 |
| Carvedilol | Carvedilol | 158 | 40 |
| Metformin Hcl | Metformin Hcl | 155 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 153 | 41 |
| Allopurinol | Allopurinol | 150 | 29 |
| Bupropion Xl | Bupropion Hcl | 147 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 39 |
| Donepezil Hcl | Donepezil Hcl | 130 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 34 |
| Furosemide | Furosemide | 126 | 47 |
| Eliquis | Apixaban | 124 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 47 |
| Warfarin Sodium | Warfarin Sodium | 123 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 15 |
| Potassium Chloride | Potassium Chloride | 121 | 38 |
| Memantine Hcl | Memantine Hcl | 111 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 27 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 107 | 106 |
| Methylprednisolone | Methylprednisolone | 107 | 89 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 21 |
| Glimepiride | Glimepiride | 97 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 21 |
| Ezetimibe | Ezetimibe | 90 | 22 |
| Sertraline Hcl | Sertraline Hcl | 89 | 22 |
| Synthroid | Levothyroxine Sodium | 87 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 20 |
| Sucralfate | Sucralfate | 83 | 14 |
| Mounjaro | Tirzepatide | 79 | 15 |
| Azithromycin | Azithromycin | 77 | 73 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 22 |
| Famotidine | Famotidine | 75 | 21 |
| Naproxen | Naproxen | 74 | 21 |
| Myrbetriq | Mirabegron | 72 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 51 |
| Mirtazapine | Mirtazapine | 69 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 11 |
| Pregabalin | Pregabalin | 66 | 20 |
| Cephalexin | Cephalexin | 64 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Alendronate Sodium | Alendronate Sodium | 60 | 14 |
| Primidone | Primidone | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | 14 |
| Diazepam | Diazepam | 53 | 20 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Aripiprazole | Aripiprazole | 52 | 17 |
| Amoxicillin | Amoxicillin | 51 | 44 |
| Etodolac | Etodolac | 51 | 16 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | suppressed |
| Lamotrigine | Lamotrigine | 50 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 43 |
| Colestipol Hcl | Colestipol Hcl | 47 | 18 |
| Ondansetron Odt | Ondansetron | 46 | 17 |
| Buspirone Hcl | Buspirone Hcl | 45 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 14 |
| Valacyclovir | Valacyclovir Hcl | 44 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 27 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Chlorthalidone | Chlorthalidone | 35 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Finasteride | Finasteride | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 16 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Cefdinir | Cefdinir | 16 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $171.07 · 10 records | PFIZER INC. | BREZTRI, LINZESS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, Senza, UBRELVY, Veozah, Xhance, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error